Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Igor Latorzeff

Showing results (61-70 of 78) with videos related to

Pageof 8
Sort By:
Cancer Radiotherapie : Journal De La Societe Francaise De Radiotherapie Oncologique|May 1, 2025
Evolution of radiation oncology training in France: Over 20 years of the role of the Société française des jeunes radiothérapeutes oncologues (SFjRO, the French society of young radiation oncologists)Audrey Larnaudie, Youssef Ghannam, Yasmine El Houat, et al.
The Lancet. Oncology|May 11, 2016
Salvage radiotherapy with or without short-term hormone therapy for rising prostate-specific antigen concentration after radical prostatectomy (GETUG-AFU 16): a randomised, multicentre, open-label phase 3 trialChristian Carrie, Ali Hasbini, Guy de Laroche, et al.
International Journal of Radiation Oncology, Biology, Physics|March 21, 2026
Pushing the boundaries of SBRT in irradiated territories for nodal oligorecurrent prostate cancer: outcomes of the CYGNUS multicentric retrospective studyEwen Anger, Stephane Supiot, Quentin Josset, et al.
Radiation Oncology (London, England)|July 5, 2023
Target volume delineation for radiotherapy of meningiomas: an ANOCEF consensus guidelineNicolas Martz, Julia Salleron, Frédéric Dhermain, et al.
The Lancet. Oncology|October 21, 2019
Short-term androgen deprivation therapy combined with radiotherapy as salvage treatment after radical prostatectomy for prostate cancer (GETUG-AFU 16): a 112-month follow-up of a phase 3, randomised trialChristian Carrie, Nicolas Magné, Patricia Burban-Provost, et al.
Clinical and Translational Radiation Oncology|March 27, 2023
Randomized phase II trial in prostate cancer with hormone-sensitive OligometaSTatic relapse: Combining stereotactic ablative radiotherapy and durvalumab (POSTCARD GETUG P13): Study protocolMaximilien Rogé, Yoann Pointreau, Paul Sargos, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|September 27, 2021
Quality assurance program and early toxicities in the phase III BONBIS randomized trial evaluating the role of a localized radiation boost in ductal carcinoma in situCeline Bourgier, Didier Cowen, Florence Castan, et al.
JAMA Oncology|February 1, 2019
Effect of Adding Docetaxel to Androgen-Deprivation Therapy in Patients With High-Risk Prostate Cancer With Rising Prostate-Specific Antigen Levels After Primary Local Therapy: A Randomized Clinical TrialStéphane Oudard, Igor Latorzeff, Armelle Caty, et al.
European Urology Oncology|April 14, 2023
Prostatectomy Bed Image-guided Dose-escalated Salvage Radiotherapy (SPIDER): An International Multicenter Retrospective StudyNicolas Benziane-Ouaritini, Thomas Zilli, Antoine Giraud, et al.
European Urology|June 26, 2025
Duration of Androgen Suppression with Postoperative Radiotherapy (DADSPORT) for Nonmetastatic Prostate Cancer: A Collaborative Systematic Review and Meta-analysis of Aggregate DataSarah Burdett, David J Fisher, Jayne F Tierney, et al.
Pageof 8

Showing results (61-70 of 78) with videos related to

Sort By:
Pageof 8
Cancer Radiotherapie : Journal De La Societe Francaise De Radiotherapie Oncologique|May 1, 2025
Evolution of radiation oncology training in France: Over 20 years of the role of the Société française des jeunes radiothérapeutes oncologues (SFjRO, the French society of young radiation oncologists)Audrey Larnaudie, Youssef Ghannam, Yasmine El Houat, et al.
The Lancet. Oncology|May 11, 2016
Salvage radiotherapy with or without short-term hormone therapy for rising prostate-specific antigen concentration after radical prostatectomy (GETUG-AFU 16): a randomised, multicentre, open-label phase 3 trialChristian Carrie, Ali Hasbini, Guy de Laroche, et al.
International Journal of Radiation Oncology, Biology, Physics|March 21, 2026
Pushing the boundaries of SBRT in irradiated territories for nodal oligorecurrent prostate cancer: outcomes of the CYGNUS multicentric retrospective studyEwen Anger, Stephane Supiot, Quentin Josset, et al.
Radiation Oncology (London, England)|July 5, 2023
Target volume delineation for radiotherapy of meningiomas: an ANOCEF consensus guidelineNicolas Martz, Julia Salleron, Frédéric Dhermain, et al.
The Lancet. Oncology|October 21, 2019
Short-term androgen deprivation therapy combined with radiotherapy as salvage treatment after radical prostatectomy for prostate cancer (GETUG-AFU 16): a 112-month follow-up of a phase 3, randomised trialChristian Carrie, Nicolas Magné, Patricia Burban-Provost, et al.
Clinical and Translational Radiation Oncology|March 27, 2023
Randomized phase II trial in prostate cancer with hormone-sensitive OligometaSTatic relapse: Combining stereotactic ablative radiotherapy and durvalumab (POSTCARD GETUG P13): Study protocolMaximilien Rogé, Yoann Pointreau, Paul Sargos, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|September 27, 2021
Quality assurance program and early toxicities in the phase III BONBIS randomized trial evaluating the role of a localized radiation boost in ductal carcinoma in situCeline Bourgier, Didier Cowen, Florence Castan, et al.
JAMA Oncology|February 1, 2019
Effect of Adding Docetaxel to Androgen-Deprivation Therapy in Patients With High-Risk Prostate Cancer With Rising Prostate-Specific Antigen Levels After Primary Local Therapy: A Randomized Clinical TrialStéphane Oudard, Igor Latorzeff, Armelle Caty, et al.
European Urology Oncology|April 14, 2023
Prostatectomy Bed Image-guided Dose-escalated Salvage Radiotherapy (SPIDER): An International Multicenter Retrospective StudyNicolas Benziane-Ouaritini, Thomas Zilli, Antoine Giraud, et al.
European Urology|June 26, 2025
Duration of Androgen Suppression with Postoperative Radiotherapy (DADSPORT) for Nonmetastatic Prostate Cancer: A Collaborative Systematic Review and Meta-analysis of Aggregate DataSarah Burdett, David J Fisher, Jayne F Tierney, et al.
Pageof 8